Gastric Cancer AVIL overexpression and pharmacologic inhibition in GES1 and AGS cell lines.
AVIL is an oncogenic driver of gastric cancer.  To test the oncogenic ability of AVIL, we established stable AVIL overexpression in normal human gastric epithelial cell line GES1 and performed RNA-sequence. We also use AVIL inhibitor compound A to treat gastric cancer cell line AGS and do transcriptome analysis. Overall design: control plasmid vs AVIL overexpression in GES1|small molecule inhibition of AVIL in gastric cancer AGS cell line DMSO vs CompoundA